Literature DB >> 31776747

Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis.

Tae-Hyung Kim1,2, Sungmin Woo3, Sangwon Han4, Chong Hyun Suh5, Dong Ho Lee1,6, Jeong Min Lee1,6,7.   

Abstract

OBJECTIVE: To perform a systematic review and meta-analysis to determine intrahepatic distant recurrence (IDR) risk of hepatobiliary phase (HBP) hypointense nodules without arterial phase hyperenhancement (APHE) on pretreatment gadoxetic acid-enhanced MRI in patients with hepatocellular carcinoma (HCC) treated with either hepatectomy or radiofrequency ablation (RFA).
METHODS: PubMed and EMBASE databases were searched up to April 6, 2019. We included studies that evaluated HBP hypointense nodules without APHE as risk factors for IDR in HCC patients treated with either hepatectomy or RFA. Hazard ratios (HR) were meta-analytically pooled using random effects model. Subgroup analyses stratified to clinicopathologic variables were performed to explore heterogeneity. Methodological quality of included studies was assessed using Quality in Prognostic Studies (QUIPS) tool.
RESULTS: Eight studies with 842 patients were analyzed. The overall pooled HR for IDR was 2.44 (95% CI, 1.99-2.98) and were 2.14 (95% CI, 1.66-2.76) and 3.07 (95% CI, 2.19-4.31) for patients that underwent hepatectomy and RFA, respectively. No significant heterogeneity was present (I2 = 0%). The presence of these nodules was consistently shown to be significant factors for IDR in other subgroups (HR = 1.74-3.07). Study quality was generally moderate.
CONCLUSIONS: HBP hypointense nodules without APHE are risk factors for IDR in HCC patients treated with either RFA or hepatectomy. Stratification of patient management with regard to performing additional tests or treatment for these nodules and modification of proper follow-up strategies may be required in patients with HCC who have these nodules on pretreatment gadoxetic acid-enhanced MRI. KEY POINTS: • HBP hypointense nodules without APHE constitute an entity that is unique in gadoxetic acid-enhanced MRI. • HBP hypointense nodules without APHE are risk factors for IDR in HCC patients treated with either RFA or hepatectomy. • Stratification of management and modification of proper follow-up strategies may be required in HCC patients who have these nodules on pretreatment gadoxetic acid-enhanced MRI.

Entities:  

Keywords:  Gd-EOB-DTPA; Hepatocellular carcinoma; Meta-analysis; Recurrence; Systematic review

Mesh:

Substances:

Year:  2019        PMID: 31776747     DOI: 10.1007/s00330-019-06499-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  3 in total

1.  Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis.

Authors:  Tae-Hyung Kim; Sungmin Woo; Sangwon Han; Chong Hyun Suh; Richard Kinh Gian Do; Jeong Min Lee
Journal:  Acad Radiol       Date:  2020-09-20       Impact factor: 5.482

Review 2.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

Review 3.  Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment.

Authors:  Marco Gatti; Cesare Maino; Fatemeh Darvizeh; Alessandro Serafini; Eleonora Tricarico; Alessia Guarneri; Riccardo Inchingolo; Davide Ippolito; Umberto Ricardi; Paolo Fonio; Riccardo Faletti
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.